1. Background {#sec0005}
=============

Historically cytomegalovirus (CMV) disease was associated with a high morbidity and mortality after solid organ transplantation.[@bib0005] In recent years, the combination of improved antiviral management and immunosuppressive strategies has minimised the health impact of CMV in this clinical setting.[@bib0010; @bib0015; @bib0020; @bib0025; @bib0030] Despite the widespread deployment of antiviral prophylaxis for high-risk patients reducing the risk of infection and disease during the prophylaxis period late infection and disease remain important clinical management challenges.[@bib0035; @bib0040; @bib0045; @bib0050] In addition, the appropriate antiviral management (prophylaxis or pre-emptive antiviral therapy) of patients at intermediate risk of infection and disease remains controversial even though these patients represent a sizeable transplanted population.[@bib0055]

While clinical trials provide essential benchmarks for drug efficacy there remains an important place for information gathered from audits across multiple centres to inform healthcare managers and physicians on the current impact that CMV has following solid organ transplantation.

2. Objectives {#sec0010}
=============

To assess the incidence of CMV syndrome/disease after solid organ transplantation especially in the recipient CMV seropositive population.

3. Study design {#sec0015}
===============

The survey was a retrospective analysis of centres that transplanted solid organs within the UK between 1/04/2004 and 31/03/2006. Patients were categorised into either those who developed an episode of symptomatic CMV infection after transplant or those who remained free of symptoms related to CMV. All patients were stratified according to their risk of CMV infection based upon donor and recipient CMV serology. Patients were followed up for 2 years for the occurrence of CMV syndrome/disease (defined below). However, patients were excluded from the final analysis if their care transferred to another centre within 2 years of follow-up.

3.1. Primary objective {#sec0020}
----------------------

The primary objective of the study was to characterise the frequency of symptomatic CMV infection after solid organ transplantation in the UK setting.

3.2. Inclusion/exclusion criteria {#sec0025}
---------------------------------

Patients who received a solid organ transplant within the UK between 1/04/2004 and 31/03/2006. There were no exclusion criteria.

3.3. Participating centres {#sec0030}
--------------------------

All UK hospitals performing adult heart, lung and liver transplantation were approached to participate in the study along with 2 centres performing kidney transplantation only. This represented 21 of 36 adult transplanting units. Nine hospitals representing 12 transplant units participated in the study. Information on the antiviral CMV management strategy in place during the study period was collected from each centre. The study was conducted in accordance with good clinical practice (GCP) guidelines.

3.4. CMV disease definitions {#sec0035}
----------------------------

CMV syndrome was defined as CMV PCR (polymerase chain reaction) viraemia plus fever of unexplained origin and one of the following signs: leucopenia, myalgia or arthralgia.[@bib0055]

CMV disease was defined according to the Ljungman et al.:[@bib0060](1)Detection of CMV by culture, histopathology, immunohistochemistry with CMV specific antibodies or in situ hybridisation in a biopsy of the affected organ.(2)CMV central nervous system (CNS) disease could be diagnosed by the presence of CMV DNA or virus culture positivity in the cerebrospinal fluid.(3)CMV retinitis diagnosed by qualified ophthalmologist.(4)CMV hepatitis diagnosed by the presence of CMV in a liver biopsy by histology (CMV inclusions or immunohistochemistry).(5)CMV colitis diagnosed by the presence of CMV in a gut biopsy by histology (CMV inclusions or immunohistochemistry).

Patients experiencing CMV viraemia without disease were classified as having asymptomatic viraemia. No data on viral load for CMV were obtained as part of the audit. In centres adopting pre-emptive therapy, CMV surveillance was undertaken by real time PCR methods (either commercial or in-house on plasma or whole blood) on a weekly basis until 3-months post transplant. Consistent post prophylaxis surveillance was not routinely adopted. Thresholds for initiation of therapy varied between centres but first-line therapy involved either intravenous ganciclovir (5 mg/kg bid) or valganciclovir (900 mg bid) and was adjusted for renal function.

3.5. Statistical analysis {#sec0040}
-------------------------

Comparison of incidence between groups was performed using the chi-squared test or Fisher\'s exact test as appropriate. *p*-values ≤0.05 were regarded as significant.

4. Results {#sec0045}
==========

Nine hospitals participated in the study performing 1807 solid organ transplants during the 2-year study period. The majority were renal transplant recipients (57.3%) with the next largest population being liver transplant recipients (28.6%). The total number of solid organ transplants carried out in the UK during the study period was 5518 (UK Transplant Registry data) and so the participating centres in our study represented 32.7% of all transplant activity occurring in the UK during the 2 year period from 2004 to 2006. The distribution of transplants amongst the 9 hospitals is shown in [Table 1](#tbl0005){ref-type="table"}.

The individual antiviral management strategies adopted for each solid organ transplant group stratified according to the donor and recipient serostatus for CMV is shown in [Table 2](#tbl0010){ref-type="table"}. In the high-risk D+R− group the majority of CMV protocols deployed antiviral prophylaxis with valganciclovir (VGCV) at 900 mg once a day for 90 days (76.4%) with the remaining protocols used a lower dose of VGCV (450 mg od for 90 days) and one heart transplant protocol deployed no prophylaxis or pre-emptive therapy in this high risk group. In the intermediate risk D+R+ group, a more diverse range of management strategies were deployed with 47% of centres performing neither prophylaxis nor pre-emptive therapy, 35% performing prophylaxis with VGCV at either 900 mg once daily or 450 mg once daily for 90 days and 17% performing pre-emptive therapy with valganciclovir at full dose. In the low risk category (D−R+), the majority of transplant units (53%) were performing neither prophylaxis nor pre-emptive therapy. With a single exception, the remaining centres followed a management strategy for the D−R+ patients that was the same as for the D+R+ group. For patients with virtually no risk of CMV infection and disease after transplantation (donor and recipient both seronegative, D−R−), the majority of CMV protocols (82.3%) undertook no antiviral prophylaxis or pre-emptive therapy. However, 3 centres adopted pre-emptive therapy for these low risk patients.

The incidence of CMV disease in the different patient populations who had achieved 2 years of follow-up stratified according to donor and recipient seropositivity is shown in [Table 3](#tbl0015){ref-type="table"}. CMV disease continues to be most prevalent in the high risk D+R− setting (despite the fact that majority of these patients were receiving prophylaxis) with an average rate of 20.5%. The rate was reduced significantly in the D+R+ group (8.1%; *p* \< 0.001 vs D+R−) but it was noteworthy that the prevalence in the lung transplant recipients was comparable to that observed in the high-risk population. The D+R+ renal transplant recipients had a 40% reduction in their incidence of CMV disease compared to the D+R− group. In the D−R+ group, the average incidence of CMV disease was lower than that observed in the D+R− group (mean 9.0%; *p* \< 0.001) and comparable to that observed in the D+R+ group although the high incidence of disease in both lung and heart transplant recipients should be noted. Overall the number of patients with CMV syndrome/disease in the recipient seropositive group was comparable to the number of cases of syndrome/disease in the D+R− group (58 cases in the R+ group vs 55 cases in the D+R− group; *p* = not significant). The incidence of overt CMV disease in the D−R− group was very low (0.1%) equating to a single liver transplant recipient.

In the context of CMV viraemia and its association with the occurrence of CMV syndrome and disease, data were available for 4 renal transplant centres and 3 liver transplant centres representing a total of 1547 patients (85.6% of the total patient evaluable). These data are summarised in [Tables 4 and 5](#tbl0020 tbl0025){ref-type="table"}, respectively. In the D+R− renal transplant recipients the overall rate of CMV viraemia was 36.2% with the rate of asymtomatic CMV viraemia relatively low at 12.1% whereas CMV syndrome with concurrent viraemia was recorded at a higher level (22.4%) and overt CMV disease only observed in one patient. In contrast, both the D+R+ and the D−R+ renal transplant groups exhibited higher levels of asymptomatic CMV viraemia (24.1% and 32.8%, respectively) compared to the D+R− group although the incidence of CMV syndrome was significantly lower in both groups compared to the high risk group (*p* = 0.026 for D+R+ and *p* = 0.0012 for the D−R+ comparison). In patients where both donor and recipient were seronegative the incidence of asymptomatic viraemia and syndrome were extremely low ([Table 4](#tbl0020){ref-type="table"}).

In a similar analysis of liver transplant recipients, the overall incidence of asymptomatic CMV viraemia was lower than that observed across all donor--recipient CMV groups after renal transplantation although it only reached statistical significance for the D−R+ comparison (*p* = 0.003). Consistent with the data in the high risk D+R− renal transplant group there was a lower rate of asymptomatic CMV viraemia (7.7%) compared to the occurrence of CMV syndrome/disease (21.3%). This effect was not observed in the other donor/recipient groups where the incidence of asymptomatic viraemia was always greater than CMV syndrome/disease ([Table 5](#tbl0025){ref-type="table"}).

We next investigated whether the management strategy adopted in the lower risk (D+R+ and D−R+) settings was associated with differences in CMV syndrome/disease incidence. In seropositive renal transplant recipients receiving a seropositive donor organ, CMV syndrome/disease was reduced by approximately 43% (10/63 to 6/65; *p* = 0.11) by the deployment of pre-emptive therapy compared to the no therapy group while in the low risk D−R+ setting a 62% reduction (3/46 to 1/40 *p* = 0.8) in incidence of CMV syndrome/disease was achieved through pre-emptive therapy. A similar comparison for pre-emptive therapy in liver transplant recipients could not be carried out but in the D+R+ group, receipt of CMV prophylaxis was associated with a 62.5% reduction (6/75 to 2/66; *p* = 0.28) in CMV syndrome/disease compared with no prophylaxis. Combining both patient groups revealed that any antiviral intervention reduced the incidence of CMV syndrome/disease by 58% (*p* = 0.033).

5. Discussion {#sec0050}
=============

Historically, CMV syndrome and disease have had a major impact on patient wellbeing after transplantation.[@bib0005] However, very few studies have attempted to quantify the impact that recent advances in clinical management has had on the incidence of CMV syndrome and disease outside of formal clinical trials. The results of the present audit show that CMV syndrome/disease remains an important and prevalent problem following solid organ transplantation in the UK. In the high risk D+R− group, the average incidence of CMV syndrome/disease was 20.5% consistent with previous data for renal and liver transplant recipients receiving 90 days of valganciclovir prophylaxis during clinical trials.[@bib0035; @bib0040; @bib0045; @bib0050] There appears to be very few viral or immunological markers that accurately predict the subset of patients who will develop CMV syndrome/disease after prophylaxis[@bib0065; @bib0070] although one study has observed that T-cell responses at day 100 were predictive of protection against symptomatic infection.[@bib0075] In the current study we observed that 75% and 65% of high risk renal and liver transplant recipients, respectively with CMV viraemia experienced CMV syndrome/disease arguing that surveillance of CMV viraemia following prophylaxis remains an important diagnostic. The utility of such an approach will depend upon the sampling frequency of CMV viraemia after the cessation of prophylaxis[@bib0080; @bib0085] as other studies have indicated that CMV viraemia post prophylaxis is not a good surrogate for impending disease.[@bib0090; @bib0095] The majority of centres still use prophylaxis for CMV in high risk patients so we believe that our audit data is an accurate reflection of current practice with the caveat that some renal transplant centres may have moved to 200 days of prophylaxis based upon the results of the recent IMPACT study.[@bib0040]

Although the high-risk D+R− solid organ group is a major concern for the transplant team, the incidence of symptomatic infection in the lower risk strata should not be ignored.[@bib0055; @bib0105] In this audit, D+R+ patients had an average incidence of CMV syndrome/disease of 8.1% although there was significant variation within the transplant groups with the lung transplant group having an incidence that was comparable with the D+R− group. Even in the D−R+ setting, CMV syndrome/disease was observed in 9.0% of patients and was particularly prevalent in recipients of heart and lung transplants. Such observations argue that correct management strategies for these intermediate risk patients need to be in place since they accounted for 58 cases of disease (51.3%) during the study period which was comparable to 55 cases observed in the D+R− group. It was also noteworthy that in the renal transplant setting pre-emptive therapy substantially reduced syndrome/disease compared to no therapy and in the liver transplant setting prophylaxis of the D+R+ group with VGCV for 90 days had a similar effect compared to no treatment. Although this audit comprised patients who were transplanted 7 years ago there is little evidence that prophylaxis has increased dramatically in this intermediate risk group possibly reflecting the lack of controlled clinical trials in this group. In addition, the incidence of CMV viraemia in patients being managed pre-emptively or undergoing no active management was comparable arguing many patients who went on to suffer early signs and symptoms of CMV were in fact assessed for CMV viraemia.

There was only one case of CMV disease in the D−R− group. This group remains at very low risk of symptomatic CMV infection and based on our data we would argue that this group requires no active antiviral management outside of general clinical awareness of the symptoms of primary CMV infection.

In conclusion, this audit indicates that, in the UK, CMV syndrome/disease remains a frequent occurrence following solid organ transplantation and centres should endeavour to ensure that management strategies across all risk groups are robust and audited regularly to minimise the impact of CMV on quality of life and ultimately graft survival.
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###### 

Distribution of patients across the 9 participating UK centres.

  Hospital ID   Kidney   Liver   Pancreas                                 Heart   Lung
  ------------- -------- ------- ---------------------------------------- ------- ----------------------------------------
  A             155      112     13[a](#tblfn0005){ref-type="table-fn"}           
  B             93       94      26[b](#tblfn0010){ref-type="table-fn"}           
  C                                                                       70      51[c](#tblfn0015){ref-type="table-fn"}
  D                      67                                                       
  E             159              28[d](#tblfn0020){ref-type="table-fn"}           
  F             216      244                                                      
  G             99                                                                
  H             313                                                               
  I                                                                       32      35
                                                                                  
  Total         1035     517     67                                       102     86

All simultaneous kidney-pancreas (SKP).

23 SKP + 3 pancreas only.

6 heart/lung + 11 single lung + 34 bi-lateral lung.

26 SKP + 2 pancreas only.

###### 

CMV antiviral management strategies deployed in different solid organ transplant recipients stratified according to CMV donor and recipient serostatus.

  Organ          Number of centres   D+R−               D+R+                                                   D−R+                                                   D−R−
  -------------- ------------------- ------------------ ------------------------------------------------------ ------------------------------------------------------ ------
  Kidney         3                   VGCV 900 mg 90 d   None                                                   None                                                   None
                 2                   VGCV 900 mg 90 d   PET                                                    PET                                                    PET
                 1                   VGCV 900 mg 90 d   VGCV 900 mg 90 d[a](#tblfn0025){ref-type="table-fn"}   VGCV 900 mg 90 d[a](#tblfn0025){ref-type="table-fn"}   None
                                                                                                                                                                      
  Liver          3                   VGCV 900 mg 90 d   None                                                   None                                                   None
                 1                   VGCV 900 mg 90 d   VGCV 900 mg 90 d                                       None                                                   None
                                                                                                                                                                      
  SPK/Pancreas   1                   VGCV 450 mg 90 d   VGCV 900 mg 90 d                                       VGCV 900 mg 90 d                                       None
                 1                   VGCV 900 mg 90 d   PET                                                    PET                                                    PET
                 1                   VGCV 900 mg 90 d   VGCV 900 mg 90 d                                       VGCV 900 mg 90 d                                       None
                                                                                                                                                                      
  Heart          1                   VGCV 450 mg 90 d   VGCV 450 mg 90 d                                       VGCV 450 mg 90 d                                       None
                 1                   None               None                                                   None                                                   None
                                                                                                                                                                      
  Lung           1                   VGCV 450 mg 90 d   VGCV 450 mg 90 d                                       VGCV 450 mg 90 d                                       None
                 1                   VGCV 900 mg 90 d   None                                                   None                                                   None

*Key*: SPK = simultaneous pancreas and kidney and (includes 1 pancreas only transplant); VGCV = valganciclovir; 900 mg = daily prophylactic dose for normal renal function; PET = pre-emptive therapy; 90 d = 90 days

Only if patient has received Campath therapy.

###### 

Incidence of CMV disease (including syndrome) in different organ transplant recipients according to their donor and recipient serostatus for CMV for patients with 2 year follow-up data, who lost their graft or died during the 2 year period.

            D+R−   D+R+   D−R+   D−R−   Unknown                           
  --------- ------ ------ ------ ------ --------- ------ ----- ----- ---- ------
  Renal     143    21.5   203    12.8   144       4.9    178   0.6   56   3.6
  Liver     73     20.5   141    5.7    142       2.8    104   0.0   19   0.0
  SPK       12     25.0   1      0.0    11        0.0    18    0.0   3    33.3
  Heart     33     6.1    16     0.0    22        18.2   31    0.0   0    0.0
  Lung(s)   17     29.4   18     22.2   26        19.2   19    0.0   6    0.0
                                                                          
  Totals    278    20.5   379    8.1    345       9.0    350   0.1   84   7.4

*Key*: SPK = simultaneous pancreas and kidney and (includes 1 pancreas only transplant).

###### 

Incidence of asymptomatic CMV viraemia in renal transplant patients and its relationship with CMV syndrome/disease in a subset of 4 transplant centres.

                          D+R−[a](#tblfn0030){ref-type="table-fn"}   D+R+[b](#tblfn0035){ref-type="table-fn"}   D−R+[b](#tblfn0035){ref-type="table-fn"}   D−R−                    
  ----------------------- ------------------------------------------ ------------------------------------------ ------------------------------------------ ------ ---- ------ ---- ------
  No CMV viraemia         37                                         63.8                                       72                                         66.7   42   65.6   78   96.3
  Asymptomatic viraemia   7                                          12.1                                       26                                         24.1   21   32.8   2    2.5
  CMV syndrome            13                                         22.4                                       8                                          7.4    1    1.6    1    1.2
  CMV disease             1                                          1.7                                        2                                          1.9    0    0.0    0    0.0

All patients received VGCV at 900 mg od (adjusted for renal function) for 90 days.

2 centres used pre-emptive therapy for CMV management.

###### 

Incidence of asymptomatic CMV viraemia in liver transplant patients and its relationship with CMV syndrome/disease in a subset of 3 transplant centres.

  Parameter               D+R−[a](#tblfn0040){ref-type="table-fn"}   D+R+[b](#tblfn0045){ref-type="table-fn"}   D+R+[c](#tblfn0050){ref-type="table-fn"}   D−R+                    
  ----------------------- ------------------------------------------ ------------------------------------------ ------------------------------------------ ------ ---- ------ ---- ------
  No CMV viraemia         37                                         71.2                                       38                                         79.2   48   92.3   93   94.0
  Asymptomatic viraemia   4                                          7.7                                        6                                          12.5   3    5.8    3    3.0
  CMV syndrome            7                                          13.5                                       4                                          8.3    1    1.9    2    2.0
  CMV disease             4                                          7.7                                        0                                          0.0    0    0.0    1    1.0

All 3 units used VGCV at 900 mg od (adjusted for renal function) for 90 days.

2 units used no proactive CMV management.

Single unit using VGCV 900 mg od (adjusted for renal function).
